Last reviewed · How we verify
ONC-841
At a glance
| Generic name | ONC-841 |
|---|---|
| Also known as | Anti-SIGLEC10 antibody |
| Sponsor | OncoC4, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors (PHASE1)
- Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ONC-841 CI brief — competitive landscape report
- ONC-841 updates RSS · CI watch RSS
- OncoC4, Inc. portfolio CI